Hjem › Multipelt myelom › Tennessee
Multipelt myelom kliniske forsøg i Tennessee
32 studier for Multipelt myelom søger deltagere på steder i Tennessee.
Byer i Tennessee
Officiel studietekst (engelsk)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, PLLC, Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07518186A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07073547A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- SCRI Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Henry-Joyce Cancer Clinic, Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Sarah Cannon Research Institute, Nashville
RekruttererFase 4
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05201781A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Sarah Cannon Research Institute, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07116616A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- SCRI Oncology Partners /ID# 278353, Nashville
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
- Vanderbilt University Medical Center, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06297226A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT07637578Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 28. aug. 2026 · NCT06375044A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 27. aug. 2026 · NCT07681596A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- GSK Investigational Site, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT07227311MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Ascension St. Thomas Hospital, Nashville
- Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
- Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
- og 2 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. aug. 2026 · NCT06152575A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Chattanooga
- GSK Investigational Site, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT05714839Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
- Vanderbilt University Medical Center, Nashville
RekruttererFase 2
Alder 18 til 70 · Alle køn · Opdateret 19. aug. 2026 · NCT07485647A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- SCRI Oncology Partners, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT06292780A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Nashville
- Research Site, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Nashville
- Research Site, Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. aug. 2026 · NCT07764978A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 6. aug. 2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 16. jul. 2026 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Baptist Memorial Hospital /ID# 280677, Memphis
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT05650632Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Vanderbilt-Ingram Cancer Center (VICC), Nashville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. jun. 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- SCRI Oncology Partners, Nashville
RekruttererFase 2
Alder 19 og opefter · Alle køn · Opdateret 4. jun. 2026 · NCT06974786Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- TriStar Bone Marrow Transplant, Nashville
- Vanderbilt- Ingram Cancer Center, Nashville
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. apr. 2026 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- TriStar Centennial Medical Center, Nashville
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 24. mar. 2026 · NCT04988555A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- Local Institution - 0008, Nashville
- Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 18. mar. 2026 · NCT06153251cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist (BHMCC), Memphis
- Vanderbilt-Ingram Cancer Center, Nashville
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 og opefter · Alle køn · Opdateret 20. jan. 2026 · NCT05366881CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Tennessee Oncology, Nashville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- SCRI Oncology Partners, Nashville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 3. jun. 2025 · NCT06119685Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.